Cargando…

AFP and eGFR are related to early and late recurrence of HCC following antiviral therapy

BACKGROUND: An unexpected recurrence of hepatocellular carcinoma (HCC) sometimes occurs in patients with hepatitis C virus (HCV) after treatment with direct-acting antivirals (DAAs). However, the characteristics of patients with HCC recurrence may differ depending on time after DAA treatment. We aim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Watanabe, Takao, Tokumoto, Yoshio, Joko, Kouji, Michitaka, Kojiro, Horiike, Norio, Tanaka, Yoshinori, Tada, Fujimasa, Kisaka, Yoshiyasu, Nakanishi, Seiji, Yamauchi, Kazuhiko, Ochi, Hironori, Hiraoka, Atsushi, Yagi, Sen, Yukimoto, Atsushi, Hirooka, Masashi, Abe, Masanori, Hiasa, Yoichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8201700/ https://www.ncbi.nlm.nih.gov/pubmed/34126947 http://dx.doi.org/10.1186/s12885-021-08401-7

Ejemplares similares

Simple new clinical score to predict hepatocellular carcinoma after sustained viral response with direct-acting antivirals
por: Watanabe, Takao, et al.
Publicado: (2023)

Destructive Thyroiditis Induced by Lenvatinib in Three Patients with Hepatocellular Carcinoma
por: Hirooka, Masashi, et al.
Publicado: (2018)

Simeprevir with peginterferon/ribavirin for patients with hepatitis C virus genotype 1: high frequency of viral relapse in elderly patients
por: Watanabe, Takao, et al.
Publicado: (2016)

Direct-acting antivirals improve survival and recurrence rates after treatment of hepatocellular carcinoma within the Milan criteria
por: Ochi, Hironori, et al.
Publicado: (2020)

Clinical Features of Adult Patients with Acute Hepatitis B Virus Infection Progressing to Chronic Infection
por: Michitaka, Kojiro, et al.
Publicado: (2014)

Clinical features of hemodialysis patients treated for hepatocellular carcinoma: Comparison between resection and radiofrequency ablation
por: Hiraoka, Atsushi, et al.
Publicado: (2017)

Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions: Multicenter analysis
por: Hiraoka, Atsushi, et al.
Publicado: (2018)

Impact of modified albumin–bilirubin grade on survival in patients with HCC who received lenvatinib
por: Tada, Toshifumi, et al.
Publicado: (2021)

Survival Improvements in Advanced Hepatocellular Carcinoma with Sequential Therapy by Era
por: Nakamura, Yoshiko, et al.
Publicado: (2023)

The Effect of the Hepatitis B Vaccine Derived from Genotype C on Infants Born to Mothers Infected with Genotype D
por: Michitaka, Kojiro, et al.
Publicado: (2020)

Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis
por: Hiraoka, Atsushi, et al.
Publicado: (2019)

Accurate reflection of hepatic venous pressure gradient by spleen stiffness measurement in patients with low controlled attenuation parameter values
por: Hirooka, Masashi, et al.
Publicado: (2021)

Does first‐line treatment have prognostic impact for unresectable HCC?—Atezolizumab plus bevacizumab versus lenvatinib
por: Hiraoka, Atsushi, et al.
Publicado: (2022)

Stimulated hepatic stellate cell promotes progression of hepatocellular carcinoma due to protein kinase R activation
por: Imai, Yusuke, et al.
Publicado: (2019)

Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting
por: Hiraoka, Atsushi, et al.
Publicado: (2020)

Nonalcoholic fatty liver with a hepatic arterial buffer response strongly associated with future metabolic disease
por: Hirooka, Masashi, et al.
Publicado: (2017)

The long noncoding RNA of RMRP is downregulated by PERK, which induces apoptosis in hepatocellular carcinoma cells
por: Yukimoto, Atsushi, et al.
Publicado: (2021)

Development of a method for measuring spleen stiffness by transient elastography using a new device and ultrasound-fusion method
por: Tanaka, Takaaki, et al.
Publicado: (2021)

Cisterna chyli as an optimal marker of tolvaptan response in severe cirrhotic ascites
por: Hirooka, Masashi, et al.
Publicado: (2022)

AFP ratio predicts HCC recurrence after liver transplantation
por: Koch, Christine, et al.
Publicado: (2020)

Combination of dual serum fluorescence, AFP and hepatic function tests is valuable to identify HCC in AFP-elevated liver diseases
por: Wang, Ting, et al.
Publicado: (2017)

Investigation of Potential Molecular Biomarkers for Diagnosis and Prognosis of AFP-Negative HCC
por: Liu, Zijing, et al.
Publicado: (2021)

Treatment on the Spleen Prevents the Progression of Secondary Sarcopenia in Patients With Liver Cirrhosis
por: Hirooka, Masashi, et al.
Publicado: (2020)

The hepatocellular carcinoma modified Gustave Roussy Immune score (HCC‐GRIm score) as a novel prognostic score for patients treated with atezolizumab and bevacizumab: A multicenter retrospective analysis
por: Hatanaka, Takeshi, et al.
Publicado: (2022)

Muscle atrophy as pre-sarcopenia in Japanese patients with chronic liver disease: computed tomography is useful for evaluation
por: Hiraoka, Atsushi, et al.
Publicado: (2015)

Heterogeneities of Site-Specific N-Glycosylation in HCC Tumors With Low and High AFP Concentrations
por: Zhao, Ting, et al.
Publicado: (2020)

Prognostic value of des-γ-carboxyprothrombin in patients with AFP-negative HCC treated with TACE
por: Sun, Hanyao, et al.
Publicado: (2022)

Role of hepatic resection in patients with intermediate‐stage hepatocellular carcinoma: A multicenter study from Japan
por: Tada, Toshifumi, et al.
Publicado: (2017)

C-reactive protein to albumin ratio predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib
por: Tada, Toshifumi, et al.
Publicado: (2022)

AFP promotes HCC progression by suppressing the HuR-mediated Fas/FADD apoptotic pathway
por: Chen, Tianke, et al.
Publicado: (2020)

Validation and optimization of AFP-based biomarker panels for early HCC detection in Latin America and Europe
por: Beudeker, Boris J.B., et al.
Publicado: (2023)

Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
por: Tada, Toshifumi, et al.
Publicado: (2022)

New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: A validation study
por: Tada, Toshifumi, et al.
Publicado: (2022)

Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma
por: Hiraoka, Atsushi, et al.
Publicado: (2020)

Upregulation of Serum Sphingosine (d18:1)-1-P Potentially Contributes to Distinguish HCC Including AFP-Negative HCC From Cirrhosis
por: Jiang, Yingying, et al.
Publicado: (2020)

Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience
por: Hiraoka, Atsushi, et al.
Publicado: (2021)

Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients
por: Sun, Xuqi, et al.
Publicado: (2021)

Methylated SEPT9 combined with AFP and PIVKA-II is effective for the detection of HCC in high-risk population
por: Zheng, Kepu, et al.
Publicado: (2023)

Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis
por: Tada, Toshifumi, et al.
Publicado: (2022)

Comparison of Surgical Resection and Percutaneous Ultrasonographic Guided Radiofrequency Ablation for Initial Recurrence of Hepatocellular Carcinoma in Early Stage following Curative Treatment
por: Ohama, Hideko, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_phjrjo85dhl4hbh38d6dtfdv4j